MAPT and Alzheimer disease: Additionally, the increase of selected protein panel, such as Aβ1-42, T-tau, P-tau, myelin basic protein, tissue inhibitors of metalloproteinases-1 (TIMP-1), NF-L, matrix metalloproteinases (MMP)-9, and MMP-2, was found to be helpful in differentiating SIVD patients with cognitive decline from AD, with a sensitivity of 89%, a specificity of 90% [20].